Clinical Trial: Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or

  • Disease Control Rate (DCR) per RECIST 1.1 assessed by central imaging vendor [ Time Frame: Up to 2 years ]
  • Duration of Response (DOR) per RECIST 1.1 assessed by central imaging vendor [ Time Frame: Up to 2 years ]
  • Progression-Free Survival (PFS) per RECIST 1.1 assessed by central imaging vedor [ Time Frame: Up to 2 years ]
  • Overall Survival (OS) [ Time Frame: Up to 2 years ]


    • Original Secondary Outcome: Disease Control Rate (DCR) [ Time Frame: Up to 2 years ]

    Information By: Merck Sharp & Dohme Corp.

    Dates:
    Date Received: May 29, 2015
    Date Started: August 2015
    Date Completion: July 2018
    Last Updated: February 16, 2017
    Last Verified: February 2017